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Abstract
Introduction. Atrophic disturbances of neurons of the limbic structures of the brain, which lead to insufficient regu-
lation of emotions and mood, cause depression. Substances with cerebroprotective activity have the ability to inhibit 
further development and even reverse atrophic damage to neurons.
Materials and methods. Using electrophysiological techniques, the cerebroprotective activity of piracetam, diacamf 
– (±)-cis-3-(2-benzimidazolyl)-1,2,2-trimethylcyclopentanone-carboxylic acid hydrochloride and the compound R-86, 
or 3,2’-spiro-pyrrolo-2-oxindole, was investigated in rat hippocampal slices. In behavioral experiments, there was 
studied the influence of the above substances, which had been administered for 20 days, on the most important mani-
festations of behavioral depression in rats caused by a five-day swim stress, such as the time of immobilization in the 
forced swim test and the indicator of preference for consuming sucrose solution. In addition, the influence of piracetam 
and diacamf was studied on the effects of the classic antidepressant imipramine.
Results and discussion. It was found that piracetam, diacamf and the compound R-86 in in vitro studies reduced the 
damage to the pyramidal hippocampal neurons caused by anoxia and aglycemia, the excitotoxic activity of N-meth-
yl-D-aspartate and oxidative stress when hydrogen peroxide was applied to the slices. Cerebroprotective activity of 
the test substances, when they are systemically administered for 20 days, is linked with their antidepressant-like effect, 
which was manifested in a decrease in the immobilization time in the swim test and an increase in the sucrose solution 
consumption indicator. Co-administration of piracetam in rats potentiated antidepressant activity of imipramine, and 
diacamf showed additive synergism with the antidepressant.
Conclusion. Substances with cerebroprotective activity in their chronic administration may show an antidepres-
sant-like effect. Those that potentiate the action of classical anidepressants can be used in conjunction with antidepres-
sants during episodes of exacerbation of the disease. Less active cerebroprotective drugs can be recommended during 
remission for its prolongation.
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Introduction
Administration of the most currently used antidepres-
sants, selective serotonin reuptake inhibitors, the thera-
peutic effect develops in 1/3 patients after several weeks 
of systematic administration of the drugs; in another 1/3 
of patients, the weakening of depression symptoms re-
quires the administration of antidepressants for many 
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months or a year; finally, the remaining 1/3 patients do 
not respond to the administration of two or more first-line 
antidepressants (Trivedi et al. 2006). New approaches to 
the development of antidepressants which do not interrupt 
the monoamines exchange are needed.
The idea that depression is caused by the atrophy of 
neurons in the cortical and limbic structures of the brain 
that control emotions and mood is the most well accepted 
now. These atrophic changes are manifested in a decre-
ased volume of pyramidal neurons, a reduced dendritic 
branching, a decreased number of dendritic spines and, 
consequently, synapses, and a decreased volume of the 
cortex and limbic structures (Duman and Aghajanian 
2012; Savitz and Drevets 2009). The consequence of the-
se changes, first of all, is impairment of the top-down cor-
tical control of the activity of subcortical limbic structu-
res, which contributes to the development of a depressive 
behavioral phenotype.
Since in experimental and clinical conditions the phar-
macological and drug substances with cerebroprotective 
action can prevent or reverse atrophic damage to the brain, 
this study was aimed at finding out the effect of nootro-
pe pyracetam and pharmacological substances diacamf 
((±)-cis-3-(2-benzimidazolyl)-1,2,2-trimethylcyclopen-
tanone-carboxylic acid hydrochloride) and the compound 
R-86 (3,2’-spiro-pyrrolo-2-oxindole) with cerebroprotec-
tive activity, which were synthesized in Kharkov National 
Pharmaceutical University, on the behavioral depression 
in rats induced by a chronic swim stress.
Materials and methods
The research was performed on white inbred rats. The 
cerebroprotective activity of the test substances was stu-
died on the slices of the hippocampus, using a standard 
electrophysiological method. The electrophysiological 
studies were performed on slices of the rat dorsal hippo-
campus. The details of the method were given in (Abra-
mets et al. 2011). The dorsal hippocampus was isolated 
from the posterior pole of the brain. The 400 µm thick 
slices were prepared using a Vibratome. In the hippo-
campal slices, using glass microelectrodes filled with 2 
M NaCl solution with tip resistance of 2-5 megohms, the 
population (p) excitatory postsynaptic potentials (EPSP) 
of pyramidal neurons of the CA1 region, which had been 
caused by electrical stimulation of Schaffer collaterals, 
were recorded extracellularly. The stimulation of synap-
tic inputs was carried out by a bipolar nickel-chromium 
electrode, with rectangular current pulses of 0.1 ms dura-
tion. The NMDA component of the pEPSP of pyramidal 
hippocampal neurons was isolated pharmacologically. To 
do this, the brain slices were superfused with Krebs so-
lution with a concentration of Mg2+ reduced to 0.2 mM 
and the addition of 10 µM of the AMPA receptor blocker 
– 6,7-dinitroquinoxalin-2,3-dione (DNQX), 50 µM of the 
non-competitive GABA receptors blocker of picrotoxin 
and 1 µM of the co-agonist of NMDA receptors, glycine.
The excitotoxic effect of NMDA was studied by the 
method proposed in (Liu et al. 2007). For this, the slices 
of the hippocampus were exposed to 50 µM of NMDA in 
the presence of 1 µM glycine for 15 min. After that, the 
slices were put in the incubator, in which in the experi-
mental group the test substances were added to the Krebs 
solution at concentrations equivalent to the systemically 
administered doses of 100 mg/kg (piracetam) or 10 mg/kg 
(diacamf and R-86), where they stayed for not less than 
1 hour. For the electrophysiological studies, the slices 
were taken 1 hour after NMDA effect terminated. Anoxia 
and aglycemia were simulated by the method from (Tian, 
Baker, 2002). The slices were placed in a chamber with 
nitrogen atmosphere in the Krebs solution, where gluco-
se was replaced by an equivalent amount of mannitol for 
7.5 min at a temperature of 32°C. Then the slices were 
put into an incubator in an aerated Krebs solution contai-
ning the test substances for the experimental group. For 
the electrophysiological studies, the slices were taken 1 
hour after the end of anoxia and aglycemia. An oxidative 
stress was simulated by the method from (de Almeida et 
al., 2008), for which the slices were exposed to H2O2 at 
a concentration of 1 mM for 30 min. After this, the slices 
were put into the incubator for 1 hour, after which they 
were used for the study. In the experimental group, the 
test substances were added to the Krebs solution.
Since the main function of neurons is the generation 
of postsynaptic and action potentials, a progressive (so-
metimes irreversible) decrease in the amplitudes of the 
pEPSP of the pyramid neurons of the CA1 region is consi-
dered to be the earliest manifestation of neuronal damage. 
If an amplitude decay of EPSP was less or significantly 
less apparent under the effect of test substances in vitro 
after applying damaging procedures, it is regarded as a 
manifestation of neuroprotective action. Each group of 
studies was performed on 5 to 12 sections of the hippo-
campus taken from 3 to 5 different rats.
The level of depressiveness in rats was assessed by 
recording the indicators of the swim test (Porsolt et al. 
1978). The rats were placed in a plexiglass cylinder 46 cm 
in diameter and 45 cm in height, filled with water (tem-
perature 23-25ºC) to a level of 30 cm from the bottom. 
On the first day, the duration of the swimming was 15 
minutes (pre-test); 24 hours later, the rats were placed in 
the water for 6 minutes, and, using videorecording, the 
basic parameters of their behavior were recorded and sto-
red in a separate file. The immobilization behavior was 
characterized by positioning the rats vertically, without 
any motion, with their forelegs pressed to the chest, hind 
legs extended, and the head above the water. The longer 
immobilization lasted, the higher level of depression of 
the animals was. 
The test of sucrose preference characterizing a hedonic 
behavior of rats was realized by the method from (Benelli 
et al. 1999). For this, on day one, the rats were placed 
in single cages with two drinking bowls filled with 1% 
sucrose solution. The next day, there was water in one 
drinking bowl, and the solution of sucrose – in the other. 
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For 23 hours on the third day, the animals were subjected 
to food and water deprivation, and then, for 60 minutes, 2 
pre-weighed drinking bowls filled with water and a solu-
tion of sucrose were returned to the cages. One hour later, 
the drinking bowls were weighed. In the next 2 hours of 
the fourth day, the animals received food and water, after 
which they were deprived of food and water for 21 hours. 
Then again, the drinking bowls were returned for 1 hour, 
and the percentage of preference for the consumption of 
sucrose solution (P) was determined by the formula:
P = the weight of consumed sucrose solution/ the weight 
of consumed liquid × 100.
The depressive syndrome was simulated by the method 
(Sun et al. 2011). For this, the rats were exposed to the 
swim stress every day for five days by placing the ani-
mals in water for 10 minutes after determining the initial 
Porsolt swim test indicators. Twenty-four hours, 10 and 
20 days after the last swimming session, the immobiliza-
tion time was determined. Piracetm at dose 100 mg/kg, 
diacamf and R-86 at a dose of 10 mg/kg was administered 
once a day intraperitoneally, starting from the first day 
after the termination of the five-day stress-inducing pro-
cedure. An equal volume of solvent (normal saline) was 
administered to the control animals. In the control and ex-
perimental animals, 24 hours later, as well as on the 10th 
and 20th days after the termination of the stress-inducing 
procedure, the changes in the parameters of Porsolt swim 
test and preferences for the consumption of sucrose solu-
tion were recorded. Each series of behavioral studies was 
performed in 6 to 8 rats. 
The research results were analyzed using the conventi-
onal methods of variation statistics and licensed Medstat 
software. For each series, the mean and standard error of 
the mean were determined. The significance of the diffe-
rences in the compared values was assessed using paired 
Student t-test.
Results and discussion
First of all, the test substances were assessed in regard 
of their capacity to improve the functional status of the 
brain, which manifests in the the ability to reduce brain 
damage caused by excitotoxic action of N-methyl-D-as-
partate, anoxia, glucose deprivation and oxidative stress. 
The rat dorsal hippocampus was chosen as an object of 
action, as it is a highly organized brain structure, extreme-
ly vulnerable to damaging effects.
With a single exposure, the test substances showed a 
moderate neuroprotective activity. However, when the 
test substances were systemically (intraperitoneally) ad-
ministered to the animals for at least 10 days, this activity 
increased significantly.
As seen in Fig. 1, due to the impact of anoxia and 
aglycemia on hippocampal slices, the amplitude of the 
pEPSP of pyramid neurons of the CA1 region in the con-
trol slices decreased from 2.7 mV to 0.35 mV, i.e. almost 
by an order of magnitude. At the same time, in the sli-
ces of the hippocampus of rats which had been treated 
by piracetam at a dose of 100 mg/kg systematically for 
10 days, anoxia and aglycemia reduced the amplitude of 
the pEPSP only three times (Fig. 1). Consequently, pi-
racetam protects hippocampal tissue from the damaging 
effects of anoxia and aglycemia. Similarly, piracetam 
and other test pharmacological substances reduce the 
damage to pyramidal neurons manifested by a decrease 
in the amplitudes of pEPSP and caused by anoxia and 
aglicemia, excitotoxic action of NMDA and oxidative 
stress. The range of cerebroprotective activity of the test 
substances is presented in Table 1.
So piracetam showed its maximum protective activity 
against the damage to neurons caused by oxidative stress 
and minimally weakens glutamate excitotoxicity. Dia-
camf markedly and nearly equally reduced disturbances 
of the vital activity of neurons caused by anoxia and oxi-
dative stress, but did not have anti-excitotoxic action. The 
compound R-86 weakened excitotoxic damage to neurons 
in the most pronounced way, and moderately counteracted 
the negative effect of the anoxia and oxidative stress on 
neurons. Finally, the classical antidepressant imipramine 
only 20 days after systemic administration to rats showed 
the attenuation of the neuronal damage caused by anoxia, 
aglycemia and exposure to hydrogen peroxide (Table 1).
Figure 1. The effect of the systemic administration of piracetam 
at a dose of 100 mg/kg for 10 days on the damage of pyramidal 
neurons caused by anoxia and aglycemia. Note: 1 – amplitude 
of pEPSP of the pyramid neurons in the control slices; 2 – am-
plitude of EPSP of the pyramid neurons in brain sections of rats 
that were administered piracetam; 3 – amplitude of EPSP of the 
pyramid neurons 1 hour after termination of anoxia and agly-
cemia in brain slices of rats, which were administered solvent.
At top left, there are samples of pEPSP averaged over 10 real-
izations and obtained in individual experiments on individual 
slices of the hippocampus of the control (top row) and experi-
mental rats (bottom row) before (left) and after (right) exposure 
to anoxia/aglycemia. Calibration: 1 mV, 10 ms. * – differences 
are significant at p<0.05.
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The severity of depressive behavior was assessed by 
increasing the immobilization time in the Porsolt swim 
test and by reducing the preference for consumption of 
sucrose solution in comparison with water, which corres-
pondingly reflect the motivational and hedonic compo-
nents of animal behavior. The fact that a five-day swim 
stress causes behavioral depression is indicated by an in-
crease in the time of immobilization of rats in the forced 
swim test to 70.2±3.6 sec versus 45.5±2.6 sec (p< 0.05) 
in the control group. In addition, under the same condi-
tions, the value of the preference for the consumption 
of sucrose solution decreased (p<0.05) from 83.6±3.4% 
to 65.4±5.5% (Table 2). Currently, it is established that 
the depressive phenotype of behavior caused by chronic 
stress is due to inhibition of the vital activity of neurons 
of the brain limbic structures, which is manifested in a 
decrease in the size of neurons and dendritic branching, 
a decrease in the density of dendritic spines and synaptic 
contacts (Silva-Gometz et al. 2003; Radley et al. 2004).
TChronic administration of the classic tricyclic anti-
depressant imipramine at a dose of 20 mg/kg for 20 days 
reversed the behavior disorders caused by chronic swim 
stress. Indeed, the immobilization time of the rats in the 
forced swim test decreased from 70.2±3.6 sec to 24.5±2.6 
sec and its value became less than that of the intact con-
trol. In addition, the value of preference for the consump-
tion of sucrose solution increased to 85.3±4.7% versus 
65.4 ± 5.5% in animals to which the solvent had been 
injected (Table 2).
Similar to the action of imipramine, chronic admi-
nistration of the test substances was accompanied by 
a decrease in the levels of helplessness and anhedonia 
caused by chronic swim stress. Thus, piracetam, diacamf 
and the compound R-86 reduced the immobilization time 
of rats in the forced swim test to 47.4±9.4 s, 41.6±3.9 
sec and 50.6±3.3 sec respectively versus 70.2±3.6 sec 
in the control animals (Table 2). On the other hand, pi-
racetam, diacamf and the compound R-86 increased the 
preference of the consumption of sucrose solution up to 
85.6±5.7% and 84.5±4.2 % and 76.7±2.9 % respectively 
versus 65.4±5.5 % of the rats which had received the 
solvent (Table 2). Consequently, the used drugs have the 
antidepressant-like action, but are not antidepressants 
like imipramine. Their difference from antidepressants 
is that with one dose delivery to the animals, they do not 
affect the time of immobilization in the forced swim test, 
while imipramine reduces the time of immobilization 
even under these conditions.
The plausible reasons for the development of 
neuroatrophic damage to the limbic structures (exclu-
ding amygdala), when exposed to chronic stress, may 
be a disruption of the expression of brain neurotrophins, 
primarily BDNF; impaired glutamate clearance and its 
accumulation in the extracellular space and excitotoxic 
damage to neurons; damage to the mitochondria leading 
to the reduction of the synthesis of high-energy com-
pounds and oppression of biosynthetic processes, and 
to an increase in the production of free radicals, trigge-
Table 2. Influence of the test substances on the immobilization time in the forced swim test and on the consumption of sucrose solu-
tion by the animals in the sucrose preference test in the control conditions and against the background of the behavioral depression 
caused by chronic swim stress
Experimental conditions Immobilization time in the forced swimming test (s)
% of the preferences of the consumption of 
sucrose solution
Intact control 45.5 ± 2.6 83.6 ± 3.4
20 days after stress termination, 
administration of the solvent
70.2 ± 3.6* 65.4 ± 5.5*
20 days after stress termination, 
administration of piracetam
47.4 ± 9.4# 85.6 ± 5.7#
20 days after stress termination, 
administration of diacamf
41.6 ± 3.9# 84.5 ± 4.2#
20 days after stress termination, 
administration of the compound R-86
50.6 ± 3.3# 76.7 ± 2.9#
20 days after stress termination, 
administration of imipramine
24.5 ± 2.6# 85.3 ± 4.7#
Note: * – differences are significant in comparison with the control at p< 0.05; # – differences are significant in comparison with the damaging effects 
of the swimming stress at p< 0.05 after 20 days of administration of the study drugs.
Table 1. The relative activity of drugs used in the study according to their effect on the test electrophysiological parameters 10 days 
after their systemic administration to rats
Options Study substances
Decrease of the studied 
parameters
Piracetam Diacamf Compound R-86 Imipramine
Glutamate exitotoxicity 1.15 ± 0.07 1.00 ± 0.10 1.40 ± 0.09 1.33 ± 0.09
Oxidative stress 3.00 ± 0.18 3.00 ± 0.21 1.87 ± 0.13 –
Anoxic damages 2.14 ± 0.15 3.09 ± 0.24 2.39 ± 0.16 1.76 ± 014
Note: Value = 1.0 –absence of the effect; the value > 1.0 indicates how many times the studied parameter has decreased.
Research Results in Pharmacology 4(3): 43–48 47
ring lipid peroxidation reactions; and, finally, the deve-
lopment of inflammation (Autry et al. 2009; Niciu et al. 
2014; Shalbuyeva et al. 2006; Haroon et al. 2017). Ac-
cording to Table 1, the test substances have the ability 
to attenuate the atrophic damage to neurons caused by 
glutamate excitotoxicity, high-energy compounds defici-
ency with a lack of oxygen, as well as lipid peroxidation. 
It is obvious that with a one dose delivery these drugs 
can not change the neurochemical processes in the brain 
limbic structures that determine the development of a 
depressive behavioral phenotype. However, with chronic 
administration, substances with cerebroprotective activi-
ty prevent further progress of pathochemical processes 
and, due an increased biosynthesis of proteins, nucleic 
acids and phospholipids, are likely to reverse the already 
formed atrophic damage to neurons.
Correction of resistance to antidepressants in patients 
with depression is quite a difficult task. In most cases, a 
combination therapy is recommended, with the addition 
of either another antidepressant (“double therapy”) or a 
drug from a different group (not an antidepressant) to en-
hance the effect of the main antidepressant – enhanced 
therapy, augmentation (Bykov et al. 2013). In this regard, 
an attempt was made to find out the nature of the impact 
of the substances (piracetam and pharmacological sub-
stances diacamf and compound R-86) with cerebroprotec-
tive activity on the antidepressant effects of imipramine in 
the simulation of behavioral depression.
Imipramine, which was chronically administered to 
rats at a dose of 20 mg/kg, reduced (p<0.05) the time of 
immobilization of rats in the swim test, as an indicator of 
helplessness, from 83.4±3.0 to 40.2±1.8 sec. In addition, 
the antidepressant weakened anhedonia, as evidenced by 
an increased indicator of the preference for the consump-
tion of sucrose solution from 66.6±2.1% to 85.5±3.4% 
(Table 3). At the same time, the chronic administration 
of impramine at a dose of 5 mg/kg (1/4 of the previously 
used dose) did not affect the manifestations of stress-in-
duced behavioral depression, such as helplessness and 
anhedony (Table 3).
However, when imipramine at a “non-effective” dose 
of 5 mg/kg was chronically administered along with pi-
racetam at a dose of 50 mg/kg, at which, when adminis-
tered independently, piracetam reduced the time of im-
mobilization to 58.6±2.7 s, the time of immobilization 
decreased (p<0.05) to 36.6±2.4 sec versus 74.4±3.6 when 
only imipramine was administered at a dose of 5 mg/kg 
(Table 3). In chronic co-administration of imipramine and 
piracetam at doses of 5 and 50 mg/kg, respectively, the 
preference for the consumption of sucrose solution incre-
ased from 66.6±2.1% in rats, to which the solvent had 
been administered, to 88.2±3.6% (p<0.05; Table 3). At 
the same time, these values were 63.6±2.7% with only 
imipramine being administered, and 71.6±2.9% with only 
piracetam being administered. Therefore, the administra-
tion of ¼ dose of imipramine and ½ dose of piracetam 
produces the same effect as the administration of the full 
dose of the antidepressant, i.e. piracetam potentiates the 
antidepressant effect of imipramine.
The different results were obtained when imipramine 
was administered with diacamf at a dose of 5 mg/kg. The 
time of immobilization of the rats in this case was reduced 
to 63.2±2.4 sec versus 74.4±3.6 sec in the rats to which 
only imipramine had been administered (Table 3). Chro-
nic administration of only diacamf at a dose of 5 mg/kg 
reduced the time of immobilization of the rats to 68.6±2.7 
sec. With regard to the preference for the consumption 
of sucrose solution, the combined administration of imi-
pramine and diacamf at a dose of 5 mg/kg to rats with 
stress-induced behavioral depression increased this indi-
cator to 78.5±3.4% versus 63.6±2.7 % in the rats to which 
only imipramine had been administered at a dose of 5 mg/
kg (Table 3). Diacamf, when chronically administered 
alone at the same dose, increased the preference for the 
consumption of sucrose solution to a level of 70.8±2.6%. 
Therefore, unlike piracetam, co-administration of partial 
doses of imipramine and diacamf gives a smaller effect 
than a full dose of the antidepressant, i.e. the effects of the 
two substances are summed (additive synergism).
On the basis of these results, it is possible to use to-
gether nootrope piracetam and antidepressants to enhance 
the action of the latter when treating patients with depres-
sion during the exacerbation of the disease. As for dia-
camf and similar substances, they are better to be used 
chronically during a remission of the disease in order to 
prolong the remission period and delay the onset of the 
next depressive episode.
Conclusion
Substances with cerebroprotective activity, when chro-
nically administered, can exhibit an antidepressant-like 
activity. Those that potentiate the action of classical anti-
depressants can be co-administered with antidepressants 
during episodes of exacerbation of the disease. Less ac-
tive cerebroprotective drugs can be recommended during 
remission for its prolongation.
Table 3. Influence of chronic 20-day administration of imipra-
mine and combinations of partial doses of imipramine and sub-
stances with cerebroprotective activity on indicators of behav-
ioral depression caused by swim stress
Study substanses The time of 
immobilization (s)
% of the preference 
of the consumption of 
sucrose solution
The solvent 83.4 ± 3.0 66.6 ± 2.1
Impramine 20 mg/kg 40.2 ± 1.8* 85.5 ± 3.4*
Impramine 5 mg/kg 74.4 ± 3.6 63.6 ± 2.7
Impramine 5 mg/kg +
Piracetam 50 mg/kg
36.6 ± 2.4# 88.2 ± 3.4#
Impramine 5 mg/kg +
Diacamf 5 mg/kg
63.2 ± 2.4# 78.5 ± 3.4#
Note: * – values significantly (p < 0.05) differ from the control; 
# – values significantly (P < 0.05) differ from the imipramine 
activity indicators administered at a dose of 5 mg/kg.
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